RxDoctor Payments Data

Swaminatha Gurudevan, MD

Cardiovascular Disease · New York, NYNPI 1265525174

Payments from drug & device makers

$15,841in general payments, 2019–2025

Across 272 payments — averaging $58.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$5K
  • Medtronic$4K
  • Boston Scientific$2K
  • Abbott$856
  • Heartflow, Inc.$812
  • Novartis$685
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$4,12826%
  • Speaking & faculty fees$280%
  • Travel & lodging$700%
  • Food & beverage$11,61473%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,841 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$61,120
Medicare patients
557
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl24$8,143
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide23$1,386
Rosuvastatin Calcium81$1,241
Ezetimibe15$754
Metoprolol Succinate30$635
Atorvastatin Calcium37$474
Amlodipine Besylate55$361
Isosorbide Mononitrate ErIsosorbide Mononitrate13$197
Nifedipine ErNifedipine13$123
Pravastatin Sodium11$49
Hydrochlorothiazide16$28

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →